Search
Fasitibant
go.drugbank.com/drugs/DB15646InvestigationalFasitibant is under investigation in clinical trial NCT02205814 (Fasitibant Intra-articular Injection in Patients With Symptomatic Osteoarthritis of the Knee).
Synonyms: 1-piperazinepentanaminium, .delta.-amino-4-((4-(((2,4-dichloro-3-(((2,4-dimethyl-8-quinolinyl)oxy)methyl)phenyl)sulfonyl)amino)tetrahydro-2h-pyran-4-yl)carbonyl)-n,n,n-trimethyl-.epsilon.Beludavimab
go.drugbank.com/drugs/DB18952InvestigationalBeludavimab is under investigation in clinical trial NCT04746183 (AGILE (Early Phase Platform Trial for COVID-19)).
Synonyms: VIR-7832 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN MONOC, IMMUNOGLOBULIN G1 (246-ALANINE,340-LEUCINE,342-GLUTAMIC ACID,438-LEUCINE,444-SERINE), ANTI-(SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 SPIKE GLYCOPROTEIN RECEPTOR-BINDING DOMAIN) (HUMAN MONOCLONALCabotegravir
go.drugbank.com/drugs/DB11751ApprovedInvestigational[A227668,L31193] Cabotegravir was granted FDA approval on 21 January 2021 in combination with rilpivirine to treat HIV-1 infection in virologically suppressed individuals. … Cabotegravir, or GSK1265744, is an HIV-1 integrase inhibitor that is prescribed with the non-nucleoside reverse transcriptase inhibitor, [rilpivirine].
Categories: Heterocyclic Compounds, 1-Ring, Organic Anion Transporter 1 InhibitorsProducts: Vocabria 400 mg/2 ml Enjeksiyonluk Uzatılmış Salımlı Süspansiyon, 1 ADET, Vocabria 600 mg/3 ml Enjeksiyonluk Uzatılmış Salımlı Süspansiyon, 1 ADETAlirocumab
go.drugbank.com/drugs/DB09302ApprovedInvestigationalAlirocumab is a biopharmaceutical that obtained FDA approval in July 2015 as a second line treatment for high cholesterol in adults whose LDL-cholesterol (LDL-C) is not controlled by the combination of … It is a human monoclonal antibody part of the family of the PCSK9 inhibitors which are a novel class of anticholesterol therapeutics. From this family, it was the first agent to receive FDA approval.
Categories: Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) InhibitorsProducts: PRALUENT SOLUTION FOR INJECTION IN A PRE-FILLED PEN 150 MG/ML, PRALUENT SOLUTION FOR INJECTION IN A PRE-FILLED PEN 75MG/MLPalivizumab
go.drugbank.com/drugs/DB00110ApprovedInvestigationalSynagis is a composite of human (95%) and murine (5%) antibody sequences. … Humanized monoclonal antibody (IgG1k) produced by recombinant DNA technology, directed to an epitope in the A antigenic site of the F protein of respiratory syncytial virus (RSV).
Categories: Respiratory Syncytial Virus Anti-F Protein Monoclonal AntibodyProducts: SYNAGIS 100 MG/1 ML IM ENJEKSIYONLUK ÇÖZELTI IÇEREN FLAKON,1 ADET, SYNAGIS 100 MG/1 ML IM ENJEKSIYONLUK ÇÖZELTI IÇEREN FLAKON, 1 ADETIluzanebart
go.drugbank.com/drugs/DB18275InvestigationalSynonyms: gamma1 heavy chain Homo sapiens (1-451) [VH (Homo sapiens IGHV5-51*01 (96.9%) -(IGHD) -IGHJ1*01 (100%), CDR-IMGT [8.8.14] (26-33.51-58.97-110)) (1-121) -Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1 CH1 K120, Immunoglobulin G1 [296-cysteine,301-glycine,306-cysteine], anti-(human triggering receptor expressed on myeloid cells 2) (human monoclonal VGL101 γ1-chain), disulfide with human monoclonal VGL101 κ-chainZamerovimab
go.drugbank.com/drugs/DB17766InvestigationalSynonyms: Immunoglobulin g1, anti-(rabies lyssavirus spike glycoprotein g) (human-mus musculus clone 1a9 .gamma.1-chain), disulfide with human-mus musculus clone 1a9 .kappa.-chain, dimerDenosumab
go.drugbank.com/drugs/DB06643ApprovedInvestigational; Both biosimilars also received marketing authorization in the EU in May 2024. … Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption via inhibiting RANK-mediated activation of
Products: XGEVA 120 MG SC. ENJEKSIYONLUK COZELTI ICEREN FLAKON, 1 ADET, PROLIA 60 MG/ML SC ENJEKSIYONLUK COZELTI ICEREN KULLANIMA HAZIR ENJEKTOR, 1 ADETCarmustine
go.drugbank.com/drugs/DB00262ApprovedInvestigational(From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). … A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesSynonyms: N,N'-Bis(2-chloroethyl)-N-nitrosoureaInterferon alfa-2b
go.drugbank.com/drugs/DB00105ApprovedInvestigationalInterferon alpha 2b (human leukocyte clone hif-sn 206 protein moiety reduced). A type I interferon consisting of 165 amino acid residues with arginine in position 23. … It is used extensively as an antiviral or antineoplastic agent.
Mixtures: Rebetron Ready To Use Solution (albumin(human)free) (6000000 Iu/ml and 200mg Capsules), Intron ACategories: Interferon Type I, Cytochrome P-450 CYP1A2 Inhibitors